Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

This document discusses a case of severe pediatric alopecia areata (AA) treated with ruxolitinib 1.5% topical cream, a Janus kinase (JAK) inhibitor. Alopecia areata is an autoimmune disorder characterized by CD8 T cell-mediated destruction of hair follicles, and while several treatments exist, there is limited evidence for their effectiveness in children. The study highlights the potential of JAK inhibitors as a treatment option for pediatric AA, although no curative treatments currently exist. This case contributes to the limited evidence supporting the use of JAK inhibitors in the pediatric population for AA.